Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Dec;6(4):405-409.
doi: 10.1007/s13300-015-0144-9. Epub 2015 Nov 4.

One Small Step for Empagliflozin, One Giant Leap for Diabetology

Sanjay Kalra  1
Affiliations

One Small Step for Empagliflozin, One Giant Leap for Diabetology

Sanjay Kalra. Diabetes Ther. 2015 Dec.

Abstract

This article discusses the recently published EMPA-REG OUTCOME trial, which assessed cardiovascular outcomes with empagliflozin therapy in persons with type 2 diabetes mellitus and coexisting cardiovascular disease. The article describes the background and challenges of modern cardiovascular outcome trials, points out the strengths of the EMPA-REG OUTCOME study, and places the results in perspective. It highlights the significant impact that these results will have on cardiovascular preventive pharmacotherapy, and on future drug development in diabetes. At the same time, it reminds readers of the limitations of the results, and lists the questions raised by, or left unanswered by, the trial.

Keywords: Canagliflozin; Cardiovascular outcomes; Dapagliflozin; Empagliflozin; Sodium-glucose co-transporter 2 (SGLT2) inhibitors; Type 2 diabetes mellitus.

PubMed Disclaimer

References

    1. Zinman B, Wanner C, Lachin JM. Glucose-lowering agent shows CV benefit in outcome trial, for the first time. N Engl J Med. 2015. doi:10.1056/NEJMoa1504720. (Epub ahead of print).
    1. Salsburg DS. The UGDP study. JAMA. 1971;218(11):1704–1705. doi: 10.1001/jama.1971.03190240056024. - DOI - PubMed
    1. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet. 1998;352(9131):854–865. doi: 10.1016/S0140-6736(98)07037-8. - DOI - PubMed
    1. Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290(4):486–494. doi: 10.1001/jama.290.4.486. - DOI - PubMed
    1. Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA. 2005;294(20):2581–2586. doi: 10.1001/jama.294.20.joc50147. - DOI - PubMed

LinkOut - more resources